share_log

SciSparc | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

SciSparc | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

SciSparc | S-8：員工福利計劃證券登記
SEC announcement ·  04/02 05:16
牛牛AI助理已提取核心訊息
SciSparc Ltd., a biopharmaceutical company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 1, 2024, for the purpose of registering 1,013,787 ordinary shares under its 2023 Share Incentive Plan. The Form S-8 registration statement is a necessary step for the company to legally grant stock options and award shares to its employees as part of the incentive plan. The shares will be available for issuance to participants of the plan, which is designed to attract and retain employees and to provide them with a stake in the company's success. The registration statement also includes references to the company's Annual Report and other legal documents that provide additional details about SciSparc's financial and operational status. The company, based in Tel Aviv, Israel, has also made provisions for the indemnification and insurance of its directors and officers, as per Israeli law and its amended and restated articles of association.
SciSparc Ltd., a biopharmaceutical company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 1, 2024, for the purpose of registering 1,013,787 ordinary shares under its 2023 Share Incentive Plan. The Form S-8 registration statement is a necessary step for the company to legally grant stock options and award shares to its employees as part of the incentive plan. The shares will be available for issuance to participants of the plan, which is designed to attract and retain employees and to provide them with a stake in the company's success. The registration statement also includes references to the company's Annual Report and other legal documents that provide additional details about SciSparc's financial and operational status. The company, based in Tel Aviv, Israel, has also made provisions for the indemnification and insurance of its directors and officers, as per Israeli law and its amended and restated articles of association.
生物製藥公司ScisPARC Ltd. 已於2024年4月1日向美國證券交易委員會（SEC）提交了註冊聲明，目的是根據其2023年股票激勵計劃註冊1,013,787股普通股。作爲激勵計劃的一部分，S-8表格註冊聲明是公司合法授予股票期權和向員工獎勵股票的必要步驟。這些股票將可供該計劃的參與者發行，該計劃旨在吸引和留住員工，併爲他們提供公司成功的利益。註冊聲明還包括對公司年度報告和其他法律文件的引用，這些文件提供了有關ScisPARC財務和運營狀況的更多詳細信息。這家總部位於以色列特拉維夫的公司還根據以色列法律及其經修訂和重述的公司章程爲其董事和高級職員的賠償和保險做出了規定。
生物製藥公司ScisPARC Ltd. 已於2024年4月1日向美國證券交易委員會（SEC）提交了註冊聲明，目的是根據其2023年股票激勵計劃註冊1,013,787股普通股。作爲激勵計劃的一部分，S-8表格註冊聲明是公司合法授予股票期權和向員工獎勵股票的必要步驟。這些股票將可供該計劃的參與者發行，該計劃旨在吸引和留住員工，併爲他們提供公司成功的利益。註冊聲明還包括對公司年度報告和其他法律文件的引用，這些文件提供了有關ScisPARC財務和運營狀況的更多詳細信息。這家總部位於以色列特拉維夫的公司還根據以色列法律及其經修訂和重述的公司章程爲其董事和高級職員的賠償和保險做出了規定。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。